vs
Side-by-side financial comparison of INTELLIGENT BIO SOLUTIONS INC. (INBS) and Lucid Diagnostics Inc. (LUCD). Click either name above to swap in a different company.
Lucid Diagnostics Inc. is the larger business by last-quarter revenue ($1.2M vs $896.8K, roughly 1.4× INTELLIGENT BIO SOLUTIONS INC.). INTELLIGENT BIO SOLUTIONS INC. runs the higher net margin — -298.6% vs -858.5%, a 560.0% gap on every dollar of revenue. On growth, INTELLIGENT BIO SOLUTIONS INC. posted the faster year-over-year revenue change (47.6% vs 3.3%). Over the past eight quarters, Lucid Diagnostics Inc.'s revenue compounded faster (7.9% CAGR vs 4.3%).
The Institute of Robotics and Intelligent Systems (IRIS) is part of the ETH Zurich, Switzerland. It replaced the existing Institute of Robotics, of the ETH Zurich in October 2002, when Prof. Bradley J. Nelson moved from the University of Minnesota, United States, to ETH Zurich, and succeeded the Prof. Dr. Gerhard Schweitzer.
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics firm focused on non-invasive screening tests for upper gastrointestinal diseases, including early detection of esophageal cancer and pre-cancerous lesions. It mainly serves healthcare providers and clinical partners across the United States, targeting at-risk patient populations.
INBS vs LUCD — Head-to-Head
Income Statement — Q2 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $896.8K | $1.2M |
| Net Profit | $-2.7M | $-10.4M |
| Gross Margin | 51.3% | — |
| Operating Margin | -293.9% | -971.0% |
| Net Margin | -298.6% | -858.5% |
| Revenue YoY | 47.6% | 3.3% |
| Net Profit YoY | -19.0% | 16.0% |
| EPS (diluted) | $-2.82 | $-0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $896.8K | — | ||
| Q3 25 | $1.1M | $1.2M | ||
| Q2 25 | $843.9K | $1.2M | ||
| Q1 25 | $728.9K | $828.0K | ||
| Q4 24 | $607.5K | $1.2M | ||
| Q3 24 | $872.3K | $1.2M | ||
| Q2 24 | $727.8K | $976.0K | ||
| Q1 24 | $823.8K | $1.0M |
| Q4 25 | $-2.7M | — | ||
| Q3 25 | $-3.0M | $-10.4M | ||
| Q2 25 | $-3.1M | $-4.4M | ||
| Q1 25 | $-2.5M | $-26.9M | ||
| Q4 24 | $-2.2M | $-11.5M | ||
| Q3 24 | $-2.7M | $-12.4M | ||
| Q2 24 | $-2.8M | $-11.0M | ||
| Q1 24 | $-3.0M | $-10.6M |
| Q4 25 | 51.3% | — | ||
| Q3 25 | 46.6% | — | ||
| Q2 25 | 39.8% | — | ||
| Q1 25 | 46.8% | — | ||
| Q4 24 | 36.7% | — | ||
| Q3 24 | 39.8% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 21.7% | — |
| Q4 25 | -293.9% | — | ||
| Q3 25 | -269.8% | -971.0% | ||
| Q2 25 | -367.5% | -978.8% | ||
| Q1 25 | -350.3% | -1508.1% | ||
| Q4 24 | -372.8% | -1033.8% | ||
| Q3 24 | -312.4% | -997.8% | ||
| Q2 24 | -386.3% | -1146.7% | ||
| Q1 24 | -358.6% | -1078.1% |
| Q4 25 | -298.6% | — | ||
| Q3 25 | -268.3% | -858.5% | ||
| Q2 25 | -366.2% | -381.7% | ||
| Q1 25 | -349.0% | -3249.8% | ||
| Q4 24 | -370.3% | -964.2% | ||
| Q3 24 | -307.9% | -1055.5% | ||
| Q2 24 | -382.5% | -1127.6% | ||
| Q1 24 | -361.5% | -1060.1% |
| Q4 25 | $-2.82 | — | ||
| Q3 25 | $-0.35 | $-0.10 | ||
| Q2 25 | $4.10 | $-0.08 | ||
| Q1 25 | $-0.44 | $-0.52 | ||
| Q4 24 | $-4.96 | $-0.17 | ||
| Q3 24 | $-0.70 | $-0.25 | ||
| Q2 24 | $9.60 | $-0.23 | ||
| Q1 24 | $-1.43 | $-0.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $740.4K | $47.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $11.1M | $25.8M |
| Total Assets | $17.7M | $53.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $740.4K | — | ||
| Q3 25 | $1.7M | $47.3M | ||
| Q2 25 | $1.0M | $31.1M | ||
| Q1 25 | $2.8M | $25.2M | ||
| Q4 24 | $2.2M | $22.4M | ||
| Q3 24 | $4.0M | $14.5M | ||
| Q2 24 | $6.3M | $24.9M | ||
| Q1 24 | $9.4M | $24.8M |
| Q4 25 | $11.1M | — | ||
| Q3 25 | $3.6M | $25.8M | ||
| Q2 25 | $3.0M | $7.9M | ||
| Q1 25 | $5.1M | $-5.4M | ||
| Q4 24 | $4.4M | $5.4M | ||
| Q3 24 | $6.1M | $6.3M | ||
| Q2 24 | $8.3M | $16.0M | ||
| Q1 24 | $11.1M | $11.9M |
| Q4 25 | $17.7M | — | ||
| Q3 25 | $10.0M | $53.2M | ||
| Q2 25 | $8.2M | $38.7M | ||
| Q1 25 | $9.6M | $32.8M | ||
| Q4 24 | $8.7M | $30.7M | ||
| Q3 24 | $11.7M | $22.6M | ||
| Q2 24 | $13.8M | $34.1M | ||
| Q1 24 | $17.0M | $32.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.6M | $-10.9M |
| Free Cash FlowOCF − Capex | $-1.6M | — |
| FCF MarginFCF / Revenue | -182.4% | — |
| Capex IntensityCapex / Revenue | 7.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.6M | — | ||
| Q3 25 | $-2.8M | $-10.9M | ||
| Q2 25 | $-2.2M | $-10.5M | ||
| Q1 25 | $-2.8M | $-12.5M | ||
| Q4 24 | $-2.3M | $-9.9M | ||
| Q3 24 | $-2.4M | $-10.2M | ||
| Q2 24 | $-2.9M | $-11.5M | ||
| Q1 24 | $-2.4M | $-12.6M |
| Q4 25 | $-1.6M | — | ||
| Q3 25 | $-2.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -182.4% | — | ||
| Q3 25 | -262.4% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 7.6% | — | ||
| Q3 25 | 6.3% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
